{
    "nct_id": "NCT05907980",
    "official_title": "A Phase Ia/Ib Open-label, Dose-escalation Study to Evaluate the Safety and Pharmacokinetics of ROSE12 as a Single Agent and in Combination With Other Anti-tumor Agents in Patients With Locally Advanced or Metastatic Solid Tumors",
    "inclusion_criteria": "* Age >= 18 years at time of signing informed consent form (ICF)\n* Eastern Cooperative Oncology Group (ECOG) PS of 0 or 1\n* Adequate hematologic and end-organ function\n* Life expectancy >= 12 weeks\n* Patients with histologic documentation of locally advanced, or metastatic solid tumor\n* [Dose-escalation Parts and Biopsy Parts]Refractory or resistant to standard therapies or standard therapies are not available\n* [Dose-escalation Parts and Expansion Part] Patients with confirmed availability of fresh tumor or representative tumor specimens\n* [Biopsy Parts] Patients with accessible lesion(s)\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Clinically significant cardiovascular or liver disease\n* Treatment with investigational therapy and anti-cancer therapy within 28 days prior to initiation of study drug\n* Any history of an immune-mediated Grade 4 adverse event attributed to prior cancer immunotherapy (other than asymptomatic elevation of serum amylase or lipase).\n* All imAEs from prior cancer immunotherapy (other than endocrinopathy managed with replacement therapy, stable vitiligo or stable alopecia) that have not resolved completely to baseline.\n* Adverse events from prior anti-cancer therapy that have not resolved to Grade â‰¤ 1 except for alopecia, vitiligo, or endocrinopathy managed with replacement therapy\n* Primary central nervous system (CNS) malignancy, untreated CNS metastases requiring any anti-tumor treatment, or active CNS metastases\n* Uncontrolled tumor-related pain\n* Uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures\n* Active or history of clinically significant autoimmune disease\n* History of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins.\n\n[Expansion Part]\n\n* Prior treatment with investigational product which has MoA of Treg depletion\n* Malignancies other than disease under study within 5 years prior to Cycle 1 Day 1",
    "miscellaneous_criteria": ""
}